50mg generic ultram
Johnson Pharmaceutical Research Institute’s Ultram(R) Tablets which is indicated 50mg generic ultram for the management of moderate to moderately severe pain. Shipments are expected 50mg generic ultram to begin immediately. Since March 2001, Able has received 14 ANDA approvals. Food and Drug Administration has approved its Abbreviated New Drug Application (ANDA) for Tramadol Hydrochloride Tablets, 50 mg. And branded products through Bertek Pharmaceuticals Inc. The company develops, manufactures and markets generic and branded human pharmaceuticals and active pharmaceutical ingredients. For further details and a discussion of such risks and uncertainties, we encourage you to read Forward-looking Statements found in our Annual Report on Form 10-K for the fiscal year ended March 31, 2001, and in our periodic reports on Forms 10-Q and 8-K (if any). Tramadol Hydrochloride Tablets are the AB-rated generic version of RW Johnson’s Ultram(R) 50mg generic ultram for the management of pain. Food and Drug Administration has granted approvable status for Tramadol Hydrochloride Tablets, 50 mg. Food and Drug Administration has granted final approval of the company’s ANDA for Tramadol Hydrochloride Tablets, 50 mg. Except for the historical matters contained herein, statements in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For a description of additional risks, and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2001 and its Form 10-Q for the three months ended March 31, 2002. Shipments 50mg generic ultram are expected to begin immediately. The company wrote the FDA in January objecting to a petition from Apotex that seeks the agency’s approval to use discontinued labeling in an application for a generic version of subsidiary Ortho-McNeil’s Ultram (tramadol 50 mg). Copies of this and other news releases may be obtained free of charge from IVAX’ web 50mg generic ultram site at http://www. Sales of Ultram are approximately $550 million. And is not affiliated with Eon Labs, Inc. Business Editors/Health & Medical Writers IVAX Corporation (AMEX:IVX) (LSE:IVX. L) announced today that it will immediately begin selling tramadol hydrochloride 50 mg tablets through its wholly owned subsidiary, IVAX Pharmaceuticals, Inc. , now that FDA approval of the Abbreviated New Drug Application 50mg generic ultram (anda) for this product has been received. Earlier in the year, Able Labs announced that it entered into an ANDA Transfer and Marketing Agreement with IVAX Pharmaceuticals, Inc. Investors are cautioned that forward-looking statements, including the statements regarding IVAX’ pending ANDAs and tentative approvals and filing schedule for ANDA submissions, involve risks and uncertainties which may affect the company’s business and prospects, including the risks that the launch of tramadol hydrochloride tablets in 50 mg strength will be delayed; that the compounds and products in the IVAX’ research pipeline will not be successfully developed, will not receive regulatory approval or will not be successfully commercialized; changing market conditions; the availability and cost of raw materials and other third party products; the impact of competitive products and pricing; that IVAX may not receive approval of its pending ANDAs or final approval of its tentatively approved ANDAs, or that if approved, the products will not be successfully commercialized; 50mg generic ultram that IVAX may not file any additional ANDAs; and other risks and uncertainties based on economic, competitive, governmental, technological and other factors discussed in the Company’s 2001 Annual Report on Form 10-K and its other filings with the Securities and Exchange Commission. There is no assurance that the Company will achieve the sales levels that will make its operations profitable or that ANDA filings 50mg generic ultram and approvals will be completed and obtained as anticipated. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise. Business and Health Editors PITTSBURGH–(BUSINESS WIRE)–June 21, 50mg generic ultram 2002 Mylan Laboratories Inc.